A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article discusses a new antipsychotic medication, Xanomeline and Trospium (Cobenfy), approved by the FDA for the treatment of schizophrenia. Xanomeline works on acetylcholine receptors, offering a novel mechanism of action different from traditional dopamine-blocking antipsychotics. The combination of Xanomeline and Trospium aims to address the cholinergic side effects of Xanomeline, making it a potentially promising treatment option. While the efficacy of Xanomeline-Trospium is comparable to other modern antipsychotics, its unique mechanism of action and tolerable side effect profile make it a valuable addition to schizophrenia treatment options. [Extracted from the article]
    • Abstract:
      Copyright of Issues in Mental Health Nursing is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)